Administration Can’t Be Trusted With Generic User Fees, Rep. Waxman Says
This article was originally published in The Pink Sheet Daily
Rep. Henry Waxman (D-Calif.) is opposing possible user fees for generic drug applications, arguing that the societal benefit of rapid generic entry justifies increased appropriations for the office
You may also be interested in...
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.
Pink Sheet reporters and editor discuss the latest coronavirus vaccine news, CMS’ effect on the future of aducanumab, as well as new assessment goals for PDUFA VII.